TORONTO, ONTARIO--(Marketwired - Jun 13, 2013) - Biologix Hair Inc. (BLGX)(BLGX) has appointed Leila Bloch, MD to the Company's Medical Advisory Board, where she will serve with Dr. David Perez-Meza, Dr. Alan J. Bauman, Dr. Edward A.M. Ball, Dr. Arthur G. Handal and Dr. Craig Ziering, Medical Advisory Board Chairman.
Dr. Leila Bloch, dermatologist and hair restoration surgeon, founded Clinica Bloch in the district of Itaim Bibi, Sao Paulo, Brazil. Leila Bloch graduated from the Faculty of Medicine, University of Sao Paula and undertook her Residency in Dermatology at the Hospital das Clinicas. She completed international internships at the Hospital Clinic, Barcelona, Spain (2004), University Hospital Zurich, Switzerland (2005), Johns Hopkins Hospital, Baltimore, MD (2007) and Jackson Memorial Hospital, Miami University, FL (2011).
In addition to providing direct patient care in her private clinic, Dr. Bloch is part of the Team Onco-Hematology of the Clinical Hospital Israelita Albert Einstein, where she specializes in chemotherapy-induced alopecia. The team is also involved with clinical research in dermo-cosmetics. Dr. Bloch participates in ongoing scientific research, has had her work published in national and international journals and participates in conferences and courses worldwide.
Leila Bloch, MD has lectured at the University UDABOL, Santa Cruz de la Sierra, Bolivia in 2010, Event Dermagenoma in August 2010, presented on chemotherapy-induced alopecia and scalp cooling at the Onco-Hematology HI Albert Einstein meeting twice in 2008 and taught at the XXV Congress of Aesthetic Dermatology, Medico University, USP in 2006. Dr. Bloch has also participated in the 6th Brazilian Congress of Surgery Hair Restoration, Brazilian Congress of the Brazilian Society of Surgery Dermalogica, at the 2010 American Academy of Dermatology Meeting, the XIII Annual Meeting of Dermatologists, State of Sao Paulo, RADESP, and the 61st and 62nd Brazilian Congress of Dermatology.
In 2001, Dr. Bloch received an award for her work "Pap for Health Professionals," and in 2004, she was the only Brazilian to join the European Hair Research Congress in Zurich. Dr. Bloch was medical collaborator of the Aesthetic Dermatology and Cosmetic Dermatology and Hair Clinic HC-USP.
Dr. Leila Bloch is a member of the International Society of Hair Restoration Surgery, the North American Hair Research Society, the Brazilian Society of Dermatology and the Brazilian Society for Dermatologic Surgery.
Biologix Chairman Ron Holland stated: "We welcome Dr. Bloch to the Company's Medical Advisory Board and appreciate her willingness to advise Biologix Hair Inc. in this capacity. Her training and experience should be a tremendous asset to the Company."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 147 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
- Company Earnings
- hair restoration